Mosaic Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mosaic Biosciences, Inc. - overview
Established
2009
Location
Boulder, CO, US
Primary Industry
Biotechnology
About
Mosaic Biosciences, Inc. focuses on discovering and developing innovative protein therapeutics, particularly therapeutic antibodies, leveraging advanced technologies to enhance drug development success for biopharmaceutical clients. Founded in 2009 and headquartered in Boulder, US, Mosaic Biosciences, Inc. specializes in developing protein therapeutics.
The company has undergone strategic growth with a recent funding round. Eric Furfine and Marty Stanton lead the company as CEOs. Mosaic has attracted significant investment, raising USD 11. 4 mn in a Series A round on June 14, 2022, led by Telegraph Hill Partners, bringing total funds raised to USD 11.
4 mn and current valuation to USD 25. 529 mn. Mosaic Biosciences specializes in the discovery and development of protein therapeutics, focusing on therapeutic antibodies. Utilizing proprietary Phage and Yeast Display libraries, the company provides end-to-end discovery capabilities, from lead discovery to in vivo studies.
Their clientele primarily includes global biopharmaceutical firms seeking to enhance drug pipelines, with engagement in key markets such as North America, Europe, and Asia. Mosaic Biosciences generates revenue through strategic partnerships and collaborations with biopharmaceutical companies. Clients contract the company's services for specific drug discovery and development phases, paying for access to their advanced technologies and scientific expertise. Revenue is derived from project milestones, including upfront payments for initial discovery and subsequent payments based on achieving clinical targets, ensuring necessary support during critical development stages.
Following the USD 11. 4 mn funding raised in June 2022, Mosaic Biosciences plans to expand its lab facility infrastructure and develop new technologies and capabilities. The growth strategy also includes increasing the business development team to enhance market presence. This funding will facilitate strategic expansions into new geographic regions and improve their service offerings.
Current Investors
HealthCare Ventures, Morgenthaler Ventures, High Country Venture
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.mosaicbio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.